Ustekinumab as induction and maintenance therapy for ulcerative colitis – national extended follow-up and a review of the literature

References

• Halper-Stromberg A, Dalal SR. The role of the microbiome in the etiology of inflammatory bowel diseases. Clin Colon Rectal Surg. 2023 Jan 25;36(2):120–126.
   PubMedGoogle Scholar
• Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019 Sep 26;381(13):1201–1214. doi: 10.1056/NEJMoa1900750
   PubMed Web of Science ®Google Scholar
• Ko Y, Paramsothy S, Yau Y, et al. Superior treatment persistence with ustekinumab in Crohn’s disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the persistence Australian national IBD cohort (PANIC) study. Aliment Pharmacol Ther. 2021 Aug;54(3):292–301. doi: 10.1111/apt.16436
   PubMed Web of Science ®Google Scholar
• Jeffrey AW, Picardo S, Menon S, et al. Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab: a retrospective study. Ann Gastroenterol. 2023 Jul;36(4):430–436. doi: 10.20524/aog.2023.0808
   PubMed Web of Science ®Google Scholar
• Abreu MT, Rowbotham DS, Danese S, et al. Efficacy and safety of maintenance ustekinumab for ulcerative colitis through 3 years: UNIFI long-term extension. J Crohns Colitis. 2022;16(8):1222–1234. doi: 10.1093/ecco-jcc/jjac030Mar3:jjac030
   PubMed Web of Science ®Google Scholar
• [cited 2023 Feb 25]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
   Google Scholar
• Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989 Mar;96(3):804–810. doi: 10.1016/0016-5085(89)90905-0
   PubMed Web of Science ®Google Scholar
• Danese S, Afif W, Abreu M, et al. UNIFI investigators. OP15 efficacy of ustekinumab for ulcerative colitis through 4 years: final clinical and endoscopy outcomes from the UNIFI long-term extension. JCC. 2023 Feb;17(S1):i19–i20. doi: 10.1093/ecco-jcc/jjac190.0015
   Google Scholar
• Mahadevan U, Naureckas S, Tikhonov I, et al. Pregnancy outcomes following periconceptional or gestational exposure to ustekinumab: review of cases reported to the manufacturer’s global safety database. Aliment Pharmacol Ther. 2022 Aug;56(3):477–490. doi: 10.1111/apt.16960
   PubMed Web of Science ®Google Scholar
• Laube R, Paramsothy S, Leong RW. Use of medications during pregnancy and breastfeeding for Crohn’s disease and ulcerative colitis. Expert Opin Drug Saf. 2021 Mar;20(3):275–292. doi: 10.1080/14740338.2021.1873948
   PubMed Web of Science ®Google Scholar
• Meserve J, Luo J, Zhu W, et al. Paternal exposure to immunosuppressive and/or biologic agents and birth outcomes in patients with immune-mediated inflammatory diseases. Gastroenterology. 2021 Jul;161(1):107–115.e3. doi: 10.1053/j.gastro.2021.03.020
   PubMed Web of Science ®Google Scholar
• Martin PL, Sachs C, Imai N, et al. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol. 2010 Oct;89(5):351–363. doi: 10.1002/bdrb.20250
   PubMed Web of Science ®Google Scholar
• Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844–854. doi: 10.1111/bjd.12214
   PubMed Web of Science ®Google Scholar
• Laube R, Selinger CP, Seow CH, et al. Australian inflammatory bowel disease consensus statements for preconception, pregnancy and breast feeding. Gut. 2023;72(6):1040–1053. doi: 10.1136/gutjnl-2022-329304
   PubMed Web of Science ®Google Scholar
• Torres J, Chaparro M, Julsgaard M, et al. European Crohn’s and colitis guidelines on sexuality, fertility, pregnancy, and lactation. J Crohns Colitis. 2023 Jan 27;17(1):1–27. doi: 10.1093/ecco-jcc/jjac115
   PubMed Web of Science ®Google Scholar
• Barbieri MA, Viola A, Cicala G, et al. Effectiveness and safety profiles of biological therapies in inflammatory bowel disease: real life data from an active pharmacovigilance project. Biomedicines. 2022 Dec 18;10(12):3280. doi: 10.3390/biomedicines10123280
   PubMed Web of Science ®Google Scholar
• Ytterberg SR, Bhatt DL, Mikuls TR, et al. ORAL surveillance investigators. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022 Jan 27;386(4):316–326. doi: 10.1056/NEJMoa2109927
   PubMed Web of Science ®Google Scholar
• Pudipeddi A, Kariyawasam V, Haifer C, et al. Safety of drugs used for the treatment of Crohn’s disease. Expert Opin Drug Saf. 2019 May;18(5):357–367. doi: 10.1080/14740338.2019.1612874
   PubMed Web of Science ®Google Scholar
• Taxonera C, Olivares D, López-García ON, et al. Meta-analysis: real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis. Aliment Pharmacol Ther. 2023 Mar;57(6):610–619. doi: 10.1111/apt.17386
   PubMed Web of Science ®Google Scholar
• Honap S, Al-Hillawi L, Baillie S, et al. Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study. Frontline Gastroenterol. 2022;13(6):517–523. doi: 10.1136/flgastro-2022-102168
   PubMed Web of Science ®Google Scholar
• Fumery M, Filippi J, Abitbol V, et al. Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study. Aliment Pharmacol Ther. 2021;54(7):944–951. doi: 10.1111/apt.16544
   PubMed Web of Science ®Google Scholar
• Chiappetta MF, Viola A, Mastronardi M, et al. One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy. Expert Opin Biol Ther. 2021 Nov;21(11):1483–1489. doi: 10.1080/14712598.2021.1981855
   PubMed Web of Science ®Google Scholar
• Hong SJ, Cleveland NK, Akiyama S, et al. Real-world Effectiveness and safety of ustekinumab for ulcerative colitis from 2 tertiary IBD centers in the United States. Crohn’s & Colitis. 2021 Jan;33(1):otab002. doi: 10.1093/crocol/otab002
   PubMedGoogle Scholar
• Chaparro M, Garre A, Iborra M, et al. Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from the ENEIDA registry. J Crohns Colitis. 2021 Nov 8;15(11):1846–1851. doi: 10.1093/ecco-jcc/jjab070
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946–1960. doi: 10.1056/NEJMoa1602773
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rebuck R, Wang Y, et al. Five-year efficacy and safety of ustekinumab treatment in Crohn’s disease: the IM-UNITI trial. Clin Gastroenterol Hepatol. 2022 Mar;20(3):578–590.e4.
   PubMed Web of Science ®Google Scholar
• Sands BE, Irving PM, Hoops T, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022 Jun 11;399(10342):2200–2211. doi: 10.1016/S0140-6736(22)00688-2
   PubMed Web of Science ®Google Scholar
• Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol. 2015;14(7):706–714.
   PubMed Web of Science ®Google Scholar